Do analysts prefer SIGA or LFVN?

Lifevantage has a consensus price target of $5.00, indicating a potential downside of 19.35%. Given Lifevantage's higher possible upside, analysts plainly believe Lifevantage is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lifevantage 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer JMAC or LFVN?

Lifevantage has a consensus target price of $5.00, suggesting a potential downside of 19.35%. Given Lifevantage's stronger consensus rating and higher probable upside, analysts clearly believe Lifevantage is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lifevantage 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, JMAC or LFVN?

Lifevantage has higher revenue and earnings than Maxpro Capital Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A Lifevantage $228.53M 0.34 $9.81M $0.45 13.78

Which has preferable earnings & valuation, LFVN or MGNX?

Lifevantage has higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lifevantage $228.53M 0.34 $9.81M $0.45 13.78 MacroGenics $149.50M 2.07 -$74.62M -$1.10 N/A

Is LFVN or MGNX more profitable?

Lifevantage has a net margin of 2.94% compared to MacroGenics' net margin of -44.79%. Lifevantage's return on equity of 23.89% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets Lifevantage 2.94% 23.89% 12.47% MacroGenics -44.79% -147.80% -28.40%

Do analysts recommend LFVN or NLTX?

Lifevantage presently has a consensus price target of $5.00, suggesting a potential downside of 19.35%. Given Lifevantage's stronger consensus rating and higher probable upside, research analysts plainly believe Lifevantage is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifevantage 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Lifevantage (LFVN) Competitors

$6.20 -0.42 (-6.34%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$6.17 -0.03 (-0.42%)

As of 06/29/2026 07:57 PM Eastern

Compare

LFVN vs. SIGA, RNAC, JMAC, MGNX, and NLTX

Should you buy Lifevantage stock or one of its competitors? MarketBeat compares Lifevantage with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lifevantage include Siga Technologies (SIGA), Cartesian Therapeutics (RNAC), Maxpro Capital Acquisition (JMAC), MacroGenics (MGNX), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry.

How does Lifevantage compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Siga Technologies has a net margin of 21.58% compared to Lifevantage's net margin of 2.94%. Lifevantage's return on equity of 23.89% beat Siga Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	21.58%	10.60%	8.94%
Lifevantage	2.94%	23.89%	12.47%

In the previous week, Siga Technologies and Siga Technologies both had 1 articles in the media. Siga Technologies' average media sentiment score of 1.87 equaled Lifevantage'saverage media sentiment score.

Company	Overall Sentiment
Siga Technologies	Very Positive
Lifevantage	Very Positive

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 2.7% of Siga Technologies shares are held by insiders. Comparatively, 22.0% of Lifevantage shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Siga Technologies has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Lifevantage has a consensus price target of $5.00, indicating a potential downside of 19.35%. Given Lifevantage's higher possible upside, analysts plainly believe Lifevantage is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Siga Technologies has higher earnings, but lower revenue than Lifevantage. Siga Technologies is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$93.78M	2.76	$23.28M	$0.27	13.37
Lifevantage	$228.53M	0.34	$9.81M	$0.45	13.78

Summary

Lifevantage beats Siga Technologies on 7 of the 12 factors compared between the two stocks.

How does Lifevantage compare to Cartesian Therapeutics?

Lifevantage (NASDAQ:LFVN) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

In the previous week, Lifevantage and Lifevantage both had 1 articles in the media. Lifevantage's average media sentiment score of 1.87 equaled Cartesian Therapeutics'average media sentiment score.

Company	Overall Sentiment
Lifevantage	Very Positive
Cartesian Therapeutics	Very Positive

Lifevantage has a net margin of 2.94% compared to Cartesian Therapeutics' net margin of -8,550.65%. Lifevantage's return on equity of 23.89% beat Cartesian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Lifevantage has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.34	$9.81M	$0.45	13.78
Cartesian Therapeutics	$2.80M	101.15	-$130.30M	-$5.90	N/A

Lifevantage presently has a consensus price target of $5.00, indicating a potential downside of 19.35%. Cartesian Therapeutics has a consensus price target of $32.60, indicating a potential upside of 238.17%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cartesian Therapeutics is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lifevantage has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Summary

Lifevantage beats Cartesian Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Lifevantage compare to Maxpro Capital Acquisition?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Lifevantage (NASDAQ:LFVN) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

Lifevantage has higher revenue and earnings than Maxpro Capital Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Lifevantage	$228.53M	0.34	$9.81M	$0.45	13.78

In the previous week, Lifevantage had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 1 mentions for Lifevantage and 0 mentions for Maxpro Capital Acquisition. Lifevantage's average media sentiment score of 1.87 beat Maxpro Capital Acquisition's score of 0.00 indicating that Lifevantage is being referred to more favorably in the news media.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Lifevantage	Very Positive

Lifevantage has a net margin of 2.94% compared to Maxpro Capital Acquisition's net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Maxpro Capital Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Lifevantage	2.94%	23.89%	12.47%

73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. Comparatively, 35.3% of Lifevantage shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Comparatively, 22.0% of Lifevantage shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Maxpro Capital Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Lifevantage has a consensus target price of $5.00, suggesting a potential downside of 19.35%. Given Lifevantage's stronger consensus rating and higher probable upside, analysts clearly believe Lifevantage is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lifevantage beats Maxpro Capital Acquisition on 10 of the 11 factors compared between the two stocks.

How does Lifevantage compare to MacroGenics?

Lifevantage (NASDAQ:LFVN) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Lifevantage has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Lifevantage currently has a consensus target price of $5.00, indicating a potential downside of 19.35%. MacroGenics has a consensus target price of $5.50, indicating a potential upside of 13.17%. Given MacroGenics' stronger consensus rating and higher probable upside, analysts plainly believe MacroGenics is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Lifevantage has higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.34	$9.81M	$0.45	13.78
MacroGenics	$149.50M	2.07	-$74.62M	-$1.10	N/A

In the previous week, Lifevantage and Lifevantage both had 1 articles in the media. Lifevantage's average media sentiment score of 1.87 beat MacroGenics' score of 0.94 indicating that Lifevantage is being referred to more favorably in the media.

Company	Overall Sentiment
Lifevantage	Very Positive
MacroGenics	Positive

Lifevantage has a net margin of 2.94% compared to MacroGenics' net margin of -44.79%. Lifevantage's return on equity of 23.89% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
MacroGenics	-44.79%	-147.80%	-28.40%

35.3% of Lifevantage shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 22.0% of Lifevantage shares are held by insiders. Comparatively, 13.6% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Lifevantage beats MacroGenics on 9 of the 15 factors compared between the two stocks.

How does Lifevantage compare to Neoleukin Therapeutics?

Lifevantage (NASDAQ:LFVN) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Lifevantage has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.34	$9.81M	$0.45	13.78
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Lifevantage has a net margin of 2.94% compared to Neoleukin Therapeutics' net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Lifevantage presently has a consensus price target of $5.00, suggesting a potential downside of 19.35%. Given Lifevantage's stronger consensus rating and higher probable upside, research analysts plainly believe Lifevantage is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

35.3% of Lifevantage shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 22.0% of Lifevantage shares are held by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lifevantage has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

In the previous week, Lifevantage had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for Lifevantage and 0 mentions for Neoleukin Therapeutics. Lifevantage's average media sentiment score of 1.87 beat Neoleukin Therapeutics' score of 0.00 indicating that Lifevantage is being referred to more favorably in the media.

Company	Overall Sentiment
Lifevantage	Very Positive
Neoleukin Therapeutics	Neutral

Summary

Lifevantage beats Neoleukin Therapeutics on 12 of the 14 factors compared between the two stocks.

Get Lifevantage News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFVN vs. The Competition

Export

Metric	Lifevantage	MED/DENTAL Industry	Medical Sector	NASDAQ Exchange
Market Cap	$83.52M	$16.43B	$6.85B	$12.20B
Dividend Yield	3.02%	1.28%	2.66%	6.22%
P/E Ratio	13.78	18.82	26.04	24.36
Price / Sales	0.34	2.31	550.39	103.01
Price / Cash	6.02	14.20	29.09	36.93
Price / Book	2.25	3.33	10.98	6.49
Net Income	$9.81M	$534.24M	$3.57B	$336.61M
7 Day Performance	1.97%	3.73%	3.06%	0.90%
1 Month Performance	-21.52%	2.94%	0.72%	-0.36%
1 Year Performance	-51.14%	1.44%	36.82%	31.26%

Lifevantage Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFVN Lifevantage	3.5575 of 5 stars	$6.20 -6.3%	$5.00 -19.4%	-51.1%	$83.52M	$228.53M	13.78	260
SIGA Siga Technologies	1.396 of 5 stars	$4.33 -0.1%	N/A	-44.1%	$310.91M	$94.57M	16.06	40	Positive News
RNAC Cartesian Therapeutics	4.3614 of 5 stars	$10.54 +5.9%	$32.60 +209.4%	-9.7%	$310.69M	$1.78M	N/A	64	Positive News
JMAC Maxpro Capital Acquisition	N/A	$22.83 +30.5%	N/A	+219.5%	$306.56M	N/A	N/A	2,021	Gap Down
MGNX MacroGenics	1.924 of 5 stars	$4.78 +4.3%	$5.50 +15.2%	+308.4%	$306.04M	$149.50M	N/A	430	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFVN) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifevantage (LFVN) Competitors

LFVN vs. SIGA, RNAC, JMAC, MGNX, and NLTX

How does Lifevantage compare to Siga Technologies?

Summary

How does Lifevantage compare to Cartesian Therapeutics?

Summary

How does Lifevantage compare to Maxpro Capital Acquisition?

Summary

How does Lifevantage compare to MacroGenics?

Summary

How does Lifevantage compare to Neoleukin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFVN vs. The Competition

Lifevantage Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifevantage (LFVN) Competitors

LFVN vs. SIGA, RNAC, JMAC, MGNX, and NLTX

How does Lifevantage compare to Siga Technologies?

Is SIGA or LFVN more profitable?

Does the media favor SIGA or LFVN?

Do insiders and institutionals hold more shares of SIGA or LFVN?

Which has more volatility & risk, SIGA or LFVN?

Do analysts prefer SIGA or LFVN?

Which has preferable valuation & earnings, SIGA or LFVN?

Summary

How does Lifevantage compare to Cartesian Therapeutics?

Does the media refer more to LFVN or RNAC?

Is LFVN or RNAC more profitable?

Which has higher earnings and valuation, LFVN or RNAC?

Do analysts recommend LFVN or RNAC?

Do institutionals and insiders believe in LFVN or RNAC?

Which has more volatility & risk, LFVN or RNAC?

Summary

How does Lifevantage compare to Maxpro Capital Acquisition?

Which has preferable valuation & earnings, JMAC or LFVN?

Does the media prefer JMAC or LFVN?

Is JMAC or LFVN more profitable?

Do insiders & institutionals have more ownership in JMAC or LFVN?

Which has more volatility and risk, JMAC or LFVN?

Do analysts prefer JMAC or LFVN?

Summary

How does Lifevantage compare to MacroGenics?

Which has more risk and volatility, LFVN or MGNX?

Do analysts prefer LFVN or MGNX?

Which has preferable earnings & valuation, LFVN or MGNX?

Does the media refer more to LFVN or MGNX?

Is LFVN or MGNX more profitable?

Do institutionals & insiders hold more shares of LFVN or MGNX?

Summary

How does Lifevantage compare to Neoleukin Therapeutics?

Which has stronger valuation and earnings, LFVN or NLTX?

Is LFVN or NLTX more profitable?

Do analysts recommend LFVN or NLTX?

Do institutionals and insiders hold more shares of LFVN or NLTX?

Which has more volatility & risk, LFVN or NLTX?

Does the media favor LFVN or NLTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFVN vs. The Competition

Lifevantage Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools